Clinical trial NCT03436680: Home-Based Neurofeedback Program in Treating Participants With Chemotherapy-Induced Peripheral Neuropathy
Official title: Feasibility of Home-Based Neurofeedback to Treat Chemotherapy-Induced Peripheral Neuropathy
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Neuropathy
Lead sponsor: M.D. Anderson Cancer Center
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2018-02-19
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This trial studies how well a home-based neurofeedback program works in treating participants with chemotherapy-induced peripheral neuropathy (nerve damage that affects motor function). Neurofeedback training is a type of therapy that uses an electroencephalograph and a computer software program to measure brain wave activity. It may help teach participants how to change their own brain waves to lower their perception of pain symptoms and improve overall quality of life.

Detailed description: PRIMARY OBJECTIVES:

I. Examine the feasibility of using a home-based neurofeedback system and dry electroencephalography (EEG) cap to treat chemotherapy-induced peripheral neuropathy (CIPN).

SECONDARY OBJECTIVES:

I. Estimate the effects of home-based neurofeedback (HBNF) on symptoms of (CIPN) versus a wait list (WL) control group in cancer patients.

II. Estimate the effects of home-based neurofeedback (HBNF), versus WL, on the cortical and subcortical brain regions associated with CIPN.

III. Estimate the effects of a HBNF on other aspects of pain, cancer-related symptoms, quality of life (QOL), and mental health.

OUTLINE: Participants are randomized to 1 of 2 groups.

GROUP I: Participants complete at least neurofeedback training sessions over 30 minutes 2 times a week for up to 5 weeks.

GROUP II: Participants receive standard of care.

After completion of study, participants are followed up at 1 week for Group I and 6 weeks for Group II.

Eligibility criteria: Inclusion Criteria:

* Patients must have the ability to understand and read English, sign a written informed consent, and be willing to follow protocol requirements.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
* Neuropathic pain score \>= 4 on a 0-10 numeric pain scale (numeric rating scale \[NRS\]) and/or grade 3 or higher neuropathic symptoms according to the National Cancer Institute's 4 point grading scale.
* Neuropathic symptoms must be related to chemotherapy (in the opinion of the treating physician).
* Patients must have had neuropathic symptoms for a minimum of 3 months.
* No plans to change pain medication regimen during the course of the study.
* Off active chemotherapy treatment for minimum of 6 months.
* Hormonal (e.g., tamoxifen or arimidex, etc.) and targeted (tarceva and avastin, etc.) therapies allowed as long as they will be continued during the course of the study.
* Willing to come to MD Anderson for the intake and follow up data acquisition and to receive their equipment.
* Willing to allow research staff to come to their homes or to return the equipment to MD Anderson (MDA) in the case of equipment malfunction.
* Have had a diagnosis of cancer treated with chemotherapy.
* Live within a 50 mile radius of MD Anderson's main campus.

Exclusion Criteria:

* Patients who are taking any antipsychotic medications.
* Patients with active central nervous system (CNS) disease, such as clinically-evident metastases or leptomeningeal disease, dementia, or encephalopathy.
* Patients who have ever been diagnosed with bipolar disorder or schizophrenia.
* Patients with known, previously diagnosed peripheral neuropathy from causes other than chemotherapy.
* Patients who have a history of head injury or who have known seizure activity.

Primary outcomes:
measure: Feasibility of a Home-Based Neurofeedback (HBNF) System
timeFrame: 6 weeks
Secondary outcomes:
measure: Effects of Home-Based Neurofeedback (HBNF) on Symptoms of Chemotherapy-Induced Peripheral Neuropathy (CIPN) Versus a Waitlist (WL) Control Group in Cancer Patients
timeFrame: Baseline and at 6 weeks
measure: Effects of Neurofeedback on the Cortical and Subcortical Brain Regions Associated with Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Effects of Home-Based Neurofeedback (HBNF) versus Waitlist (WL) Control Group determined by EEG,
timeFrame: Baseline and at 6 weeks
measure: Effects of Home-Based Neurofeedback (HBNF) on Other Aspects of Cancer-Related Symptoms Using Patient Surveys
timeFrame: Baseline and within 7 days of the conclusion of treatment.
measure: Effects of Home-Based Neurofeedback (HBNF) on Symptoms of Chemotherapy-Induced Peripheral Neuropathy (CIPN) Versus a Waitlist (WL) Control Group in Cancer Patients
timeFrame: Baseline and at 6 weeks
measure: Effects of Neurofeedback on the Cortical and Subcortical Brain Regions Associated with CIPN Determined by Changes in EEG as Measured by Low Resolution Electromagnetic Tomography (LORETA).
timeFrame: Baseline and at 6 weeks
Other outcomes:
Locations:
Study officials:
affiliation: M.D. Anderson Cancer Center
name: Sarah Prinsloo
role: PRINCIPAL_INVESTIGATOR
References: